PICKERING GRANT sold $110K of PCVX (indirect holdings)
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 2,000 indirectly-held shares of Vaxcyte, Inc. (PCVX) at an average of $55.23 ($54.22–$56.27, $0.11M total) across 6 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market sale amount, share count, price range, and confirmation that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this specific disclosure lacks any fundamental catalyst beyond routine planned selling.
What to watch
The sale is indirect and spread across multiple trades; without context on total holdings, it’s hard to infer conviction or magnitude versus prior plans.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
SEC Form 4 shows Vaxcyte CEO Pickering Grant sold $110,465 of PCVX shares via an open-market sale under a 10b5-1 plan on 2026-06-26.
Likely limited near-term impact; any effect should fade unless accompanied by other negative catalysts.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational/regulatory/financial disclosure in the text.
Market effects
Minimal; this is company-specific insider liquidity rather than a sector-wide signal.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as reduced confidence, especially if it coincides with other negative news (not present here).
Key entities
- issuerVaxcyte, Inc.
Company whose shares were sold by an insider; ticker PCVX.
- insiderPickering Grant
Chief Executive Officer and director who sold shares; transaction executed under a 10b5-1 plan.
